JP2019504030A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504030A5
JP2019504030A5 JP2018532747A JP2018532747A JP2019504030A5 JP 2019504030 A5 JP2019504030 A5 JP 2019504030A5 JP 2018532747 A JP2018532747 A JP 2018532747A JP 2018532747 A JP2018532747 A JP 2018532747A JP 2019504030 A5 JP2019504030 A5 JP 2019504030A5
Authority
JP
Japan
Prior art keywords
zika virus
virus vaccine
vaccine
seq
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504030A (ja
JP6949027B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/082664 external-priority patent/WO2017109225A1/en
Publication of JP2019504030A publication Critical patent/JP2019504030A/ja
Publication of JP2019504030A5 publication Critical patent/JP2019504030A5/ja
Application granted granted Critical
Publication of JP6949027B2 publication Critical patent/JP6949027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532747A 2015-12-23 2016-12-23 ジカウイルスワクチン Active JP6949027B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585.4 2015-12-23
EP15202585 2015-12-23
EP16161068 2016-03-18
EP16161068.8 2016-03-18
EP16176025 2016-06-23
EP16176025.1 2016-06-23
EP16176049 2016-06-23
EP16176049.1 2016-06-23
EP16182845 2016-08-04
EP16182845.4 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (3)

Publication Number Publication Date
JP2019504030A JP2019504030A (ja) 2019-02-14
JP2019504030A5 true JP2019504030A5 (https=) 2019-12-26
JP6949027B2 JP6949027B2 (ja) 2021-10-20

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532747A Active JP6949027B2 (ja) 2015-12-23 2016-12-23 ジカウイルスワクチン

Country Status (19)

Country Link
US (14) US11331382B2 (https=)
EP (9) EP3393509B1 (https=)
JP (1) JP6949027B2 (https=)
KR (1) KR102950500B1 (https=)
CN (2) CN115381934A (https=)
AU (1) AU2016375338B2 (https=)
BR (1) BR112018012873A2 (https=)
CA (1) CA3009278A1 (https=)
DK (1) DK3393510T5 (https=)
ES (4) ES2950887T3 (https=)
FI (1) FI3393510T3 (https=)
HR (1) HRP20230273T1 (https=)
HU (1) HUE061679T2 (https=)
LT (1) LT3393510T (https=)
MX (1) MX2018007627A (https=)
PL (1) PL3393510T3 (https=)
SG (1) SG11201805120YA (https=)
SI (1) SI3393510T1 (https=)
WO (6) WO2017109227A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
UA126548C2 (uk) * 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2020004543A (es) * 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
CN116983398A (zh) * 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CN107904215B (zh) * 2017-12-27 2021-07-27 华农(肇庆)生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
MX420109B (es) 2018-03-26 2025-02-10 Boehringer Ingelheim Animal Health Usa Inc Metodo para producir una composicion inmunogenica
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
AU2020211990A1 (en) * 2019-01-22 2021-08-12 2Seventy Bio, Inc. Methods and systems for manufacturing viral vectors
EP3965811A1 (en) * 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
WO2021028407A1 (en) 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
IL290458B2 (en) 2019-08-09 2025-06-01 Valneva Se Chikungunya vaccine formulations
WO2021048221A1 (en) * 2019-09-09 2021-03-18 Valneva Austria Gmbh Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
EP4114456A1 (en) 2020-03-06 2023-01-11 The Colorado State University Research Foundation Production of vaccines comprising inactivated sars-cov-2 viral particles
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化SARS—CoV—2病毒疫苗
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン,インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン,インコーポレイテッド 抗原の効力を決定するための方法
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
US20250381261A1 (en) * 2022-02-09 2025-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
EP1025209B1 (en) * 1997-08-28 2007-02-28 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
DE69942525D1 (de) * 1998-09-02 2010-08-05 Us Government Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
EP2073839B1 (en) * 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
CA2721870C (en) * 2008-04-21 2020-12-22 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
WO2010062396A2 (en) * 2008-11-26 2010-06-03 Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
ES2647882T3 (es) 2011-12-06 2017-12-27 Valneva Austria Gmbh Compuestos de aluminio para su uso en productos terapéuticos y vacunas
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3

Similar Documents

Publication Publication Date Title
JP2019504030A5 (https=)
US11207397B2 (en) Virus purification
JP5129805B2 (ja) 細胞培養物から精製水疱性口内炎ウイルスを単離するための精製プロセス
TW202203967A (zh) 不活化SARS—CoV—2病毒疫苗
JPWO2000020565A1 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
US20240293531A1 (en) Inactivated sars-cov-2 virus vaccine
HK40103263A (en) Virus purification
HK40106064A (en) Virus purification
HK1261326A1 (en) Virus purification
HK1261326B (en) Virus purification
HK1261562A1 (en) Virus purification
HK1261562B (en) Virus purification
AU2007221746A1 (en) Improvements in virus production